Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Top Stada Executives Resign, New Takeover Offers May Be Considered

By Stada Arzneimittel AG | July 5, 2017

Stada Arzneimittel AG appoints new chief executive officer and chief financial officer—incumbents step down from their positions.

The supervisory board of Stada Arzneimittel AG has appointed Engelbert Coster Tjeenk Willink (56) as chief executive officer with immediate effect. The duties of chief financial officer will be taken over with immediate effect by Dr. Bernhard Düttmann (57).

They replace incumbent chief executive officer Dr. Matthias Wiedenfels and chief financial, marketing, and sales officer Helmut Kraft, who have informed the supervisory board that they will step down from their positions with immediate effect for personal reasons.

“The supervisory board has been working for many months to complete the executive board and to find the best team to make the company fit for the future,” said Ferdinand Oetker, chairman of the supervisory board of Stada Arzneimittel AG. “The supervisory board of Stada accepts the personal decisions taken by Dr. Wiedenfels and Mr. Kraft. “Our operational business is unaffected by this, and we do not deviate from our operating and financial targets. Should further takeover offers be made, we will examine and evaluate them impartially.”

Alongside his duties as chief executive officer, Tjeenk Willink will also be responsible for marketing and operations. He has 25 years of experience in the pharmaceutical industry and was until 2012 a member of the executive board of Boehringer Ingelheim. Since then, he has been a member of numerous supervisory boards in the sector.

New chief financial officer Düttman was until 2015 CFO of Lanxess AG, the DAX company, and prior to that was CFO at Beiersdorf AG, another DAX listed company. Both members of the executive board were appointed until the end of the year on an interim basis. Dr. Barthold Piening, executive board member responsible for production and development, will continue his duties unchanged.

Oetker confirmed that medium-term growth targets for 2019, announced on March 17, 2017 remain unchanged. The company expects consolidated sales of between Euro 2.65 and 2.7 billion, adjusted EBITDA of between Euro 570 and 590 million, and consolidated group profit of between Euro 250 and 270 million.

(Source: Stada Arzneimittel AG)


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE